Chiropractor Dr. Jones explains how he says nootropic peptides like Selank, Semax and Dihexa work. None of these are approved drugs in the US.
Recap by typeshit. Full story at Dr. Jones, DC.
Researchers compared short-term glycemic response to tirzepatide in type 2 diabetes patients based on whether they had used incretin drugs before.
Part of his GLP-1 series, Krittanawong discusses whether the drugs could help MASLD and MASH, and how visceral fat can drive metabolic problems unseen.
16:32
Dr. Kevin Joseph, DO, who treats liver disease daily, shares his views on peptides. The claims are his own, not established treatment guidance.
Dr. Jonathan Stegall shares the data: about 13 in 100 GLP-1 users with stage 1 to 3 colorectal cancer saw it spread, versus about 22 in 100 on another diabetes drug.
She sorts skincare peptides into three main groups, starting with signalling peptides that she says prompt more collagen production.
He says shedding tied to GLP-1 drugs usually passes, but can linger, and points to telogen effluvium triggered by fast weight loss.
Loading…